ADRB2 and asthma: Future studies are warranted to target this receptor in exploring the mechanisms of β2AR inverse agonists; 2) in spite of the verified safety of βAR inverse agonist in the treatment of asthma, large amount of evidence-based and epidemiological data also showed that selective β-blockers are not completely risk-free.